Plus Therapeutics Gains Blue Shield Coverage, Remains Short of Expansion Goals
Event summary
- Plus Therapeutics’ subsidiary, CNSide Diagnostics, secured payer coverage from Blue Shield of California for its CNSide® CSF assay, effective April 2026.
- The coverage expands CNSide’s covered lives to approximately 81 million, up from 75 million.
- Plus Therapeutics aims to reach 150 million covered lives by 2026, indicating a significant gap remains.
- The CNSide® CSF Assay Platform has been used in over 11,000 tests across 120 U.S. cancer institutions since 2020.
- The assay has demonstrated a 92% sensitivity and 95% specificity, influencing treatment decisions in 90% of cases.
The big picture
The agreement with Blue Shield of California represents a continued, albeit slow, expansion of market access for CNSide, a niche diagnostic test for a difficult-to-diagnose cancer. While the company has secured coverage from several payers, the significant gap between current coverage and the stated 2026 objective highlights the challenges of navigating the complex U.S. healthcare reimbursement landscape. The assay's ability to influence treatment decisions and reduce healthcare costs, as suggested by the company, will be key to sustaining payer interest and driving broader adoption.
What we're watching
- Coverage Expansion
- The pace at which Plus Therapeutics secures additional payer coverage will be critical to achieving its 150 million covered lives target, and the terms of those agreements will impact profitability.
- Adoption Rate
- How effectively Plus Therapeutics can drive adoption of the CNSide assay within oncology centers, despite the reimbursement coverage, will determine the test’s overall market penetration.
- Clinical Utility
- Continued demonstration of the assay's clinical utility and cost-effectiveness, beyond the existing data, will be necessary to maintain payer coverage and attract new customers.
Related topics